AIM CONCEPT INTEGRATION
3rd Year MBBS
Cardiovascular System
3rd Year MBBS
Cardiovascular System
“`
Acute Coronary Syndrome, Myocardial Infarction and Antithrombotic Therapy
A rapid integration of coronary plaque disruption, myocardial ischemic injury, clinical risk assessment and the actions, monitoring and major cautions of antiplatelet, anticoagulant and thrombolytic therapy.
“`
1. THE TOPIC IN ONE CONNECTED FLOW
“`
Acute coronary syndrome develops when coronary blood flow suddenly falls, usually after disruption of an atherosclerotic plaque and formation of a platelet-rich thrombus. The degree and duration of obstruction determine whether the patient develops unstable angina, NSTEMI or STEMI. Early recognition, risk stratification and antithrombotic therapy aim to restore flow and limit myocardial damage.
1. Plaque Disruption
A vulnerable coronary plaque undergoes rupture or erosion → subendothelial collagen and tissue factor become exposed.
→
2. Thrombus Formation
Platelets adhere, activate and aggregate while the coagulation cascade generates fibrin → coronary thrombus enlarges.
→
3. Coronary Obstruction
Partial or intermittent obstruction causes unstable angina or NSTEMI, while persistent complete obstruction commonly causes STEMI.
→
4. Myocardial Injury
Reduced oxygen supply → ATP depletion and loss of contractility → prolonged ischemia causes irreversible coagulative necrosis.
→
5. Clinical Recognition
Ischemic chest pain, autonomic symptoms, ECG changes and cardiac biomarkers identify ACS and help distinguish unstable angina, NSTEMI and STEMI.
→
6. Antithrombotic Action
Antiplatelets reduce platelet aggregation, anticoagulants suppress fibrin formation and thrombolytics dissolve fibrin-rich thrombi when indicated.
→
7. Outcome
Rapid reperfusion and prevention of further thrombosis → smaller infarct size and fewer complications; delay increases heart failure, arrhythmia, mechanical rupture and death.
“`
2. KEY CLINICAL CONNECTIONS
“`
ACS Spectrum and Myocardial Damage
Ischemia without necrosis → unstable angina → no rise in cardiac biomarkers.
Ischemia with necrosis → myocardial infarction → raised cardiac biomarkers; subendocardial injury commonly produces NSTEMI, while transmural injury is associated with STEMI.
Antiplatelet and Thrombolytic Therapy
Aspirin, P2Y12 inhibitors and glycoprotein IIb/IIIa inhibitors act at different stages of platelet activation → reduce arterial thrombus growth → bleeding is the major shared adverse effect.
Thrombolytics convert plasminogen to plasmin → fibrin breakdown and reperfusion → major bleeding and intracranial haemorrhage are important risks.
Heparin, Direct Inhibitors and Warfarin
Unfractionated heparin enhances antithrombin activity against thrombin and factor Xa → rapid anticoagulation → monitor with aPTT; protamine treats major overdose.
LMWH has a more predictable, mainly anti-Xa effect → less routine monitoring and lower risk of heparin-induced thrombocytopenia than UFH.
Direct Xa and IIa inhibitors block a single activated factor, while warfarin reduces vitamin K-dependent clotting-factor synthesis → slower onset and INR monitoring.
Risk Stratification and Complications
Symptoms, ECG findings, biomarkers, haemodynamic status and clinical risk features → determine urgency of reperfusion, intensity of antithrombotic therapy and level of monitoring.
Larger or delayed infarction → greater risk of arrhythmias, acute left ventricular failure, cardiogenic shock, pericarditis, mural thrombosis and mechanical complications.
“`
3. AIM HIGH-YIELD INTEGRATION REVIEW
“`
⭐ 1. Plaque rupture or erosion → platelet activation plus coagulation → coronary thrombus → unstable angina, NSTEMI or STEMI depending on the degree and duration of obstruction.
⭐ 2. Prolonged myocardial ischemia → ATP depletion, membrane injury and irreversible coagulative necrosis → biomarker release and loss of contractile function.
3. Unstable angina causes ischemic symptoms without myocardial necrosis, whereas NSTEMI and STEMI produce necrosis and raised cardiac biomarkers.
⭐ 4. Antiplatelet drugs interrupt platelet activation or aggregation → reduced arterial thrombus extension; bleeding is the major class-wide caution.
5. Thrombolytic drugs activate plasminogen → plasmin formation → fibrin clot breakdown and reperfusion; their major danger is severe bleeding, especially intracranial haemorrhage.
6. UFH acts rapidly and requires aPTT monitoring, while LMWH has more predictable anti-Xa activity, a longer effect and usually does not require routine laboratory monitoring.
⭐ 7. Warfarin inhibits synthesis of vitamin K-dependent clotting factors → delayed anticoagulation and INR monitoring; vitamin K intake, many medicines and liver function can alter its effect.
8. Increasing infarct size and delayed reperfusion → greater risk of arrhythmia, heart failure, cardiogenic shock, mechanical rupture, mural thrombosis and death.
AIM Exam Trap
Heparin and warfarin do not have the same onset. Heparin acts rapidly on circulating clotting factors, while warfarin acts slowly because existing vitamin K-dependent factors must first be cleared; therefore, immediate anticoagulation may require heparin before warfarin becomes effective.
“`